BackDicerna Pharmaceuticals Overview

Dicerna Pharmaceuticals Long Term Debt

Dicerna Pharmaceuticals's long-term debt is $60M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$59.52M

Peer trimmed avg / median

Loading

Dicerna Pharmaceuticals Long Term Debt History

Loading

Dicerna Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Dicerna Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Dicerna Pharmaceuticals (DRNA) FAQ

Dicerna Pharmaceuticals (DRNA) currently reports a long-term debt of $60M as of September 2021. In the prior-year period, the figure was $0. Use the charts on this page to explore Dicerna Pharmaceuticals's long-term debt history and peer comparisons.

Dicerna Pharmaceuticals's long-term debt changed from $0 to $60M (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dicerna Pharmaceuticals reported $60M in long-term debt as of September 2021. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $60M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Dicerna Pharmaceuticals, and consider following DRNA for alerts when major investors trade the stock.

Dicerna Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $60M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRNA with unrelated industries.